ÂÜÀòÂÒÂ×

Sarah Dolman is a highly experienced professional in the healthcare and life sciences sectors, currently serving as a SBIR/STTR Panelist and Reviewer at the National Science Foundation since January 2024. As a Partner at Recon Strategy since November 2020, Sarah provides insights on product opportunities and business plans for life-sciences clients, while also contributing as a Senior Advisor across various healthcare engagements. Involved as a Mentor at Endless Frontier Labs, Sarah supports the transformation of scientific breakthroughs into high-growth businesses. Additional roles include Board Member at NanoPharmaSolutions, Independent Consultant for Biotech & Healthtech Startups at Healthtech Catalyst, and previous positions at Verily Life Sciences, Horizon Blue Cross Blue Shield of New Jersey, The Boston Consulting Group, and Merck, where Sarah developed strategic initiatives and led cross-functional teams. Educational credentials include a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology, an MBA from NYU Stern School of Business, and an Hon. B. Sc. in Chemistry & Mathematics from the University of Toronto.